Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic. Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave. Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37). Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making. Lay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes.

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Granito A.;Brandi G.;
2021

Abstract

Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic. Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave. Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37). Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making. Lay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes.
Munoz-Martinez S.; Sapena V.; Forner A.; Nault J.-C.; Sapisochin G.; Rimassa L.; Sangro B.; Bruix J.; Sanduzzi-Zamparelli M.; Holowko W.; El Kassas M.; Mocan T.; Bouattour M.; Merle P.; Hoogwater F.J.H.; Alqahtani S.A.; Reeves H.L.; Pinato D.J.; Giorgakis E.; Meyer T.; Villadsen G.E.; Wege H.; Salati M.; Minguez B.; Di Costanzo G.G.; Roderburg C.; Tacke F.; Varela M.; Galle P.R.; Alvares-da-Silva M.R.; Trojan J.; Bridgewater J.; Cabibbo G.; Toso C.; Lachenmayer A.; Casadei-Gardini A.; Toyoda H.; Ludde T.; Villani R.; Matilla Pena A.M.; Guedes Leal C.R.; Ronzoni M.; Delgado M.; Perello C.; Pascual S.; Lledo J.L.; Argemi J.; Basu B.; da Fonseca L.; Acevedo J.; Siebenhuner A.R.; Braconi C.; Meyers B.M.; Granito A.; Sala M.; Rodriguez-Lope C.; Blaise L.; Romero-Gomez M.; Pinero F.; Gomez D.; Mello V.; Pinheiro Alves R.C.; Franca A.; Branco F.; Brandi G.; Pereira G.; Coll S.; Guarino M.; Benitez C.; Anders M.M.; Bandi J.C.; Vergara M.; Calvo M.; Peck-Radosavljevic M.; Garcia-Juarez I.; Cardinale V.; Lozano M.; Gambato M.; Okolicsanyi S.; Morales-Arraez D.; Elvevi A.; Munoz A.E.; Lue A.; Iavarone M.; Reig M.
File in questo prodotto:
File Dimensione Formato  
Assessing the impact of COVID-1.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 487.49 kB
Formato Adobe PDF
487.49 kB Adobe PDF Visualizza/Apri
mmc4.zip

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 2.09 MB
Formato Zip File
2.09 MB Zip File Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/876019
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 23
social impact